

News release 30 March 2016

PHYZAT ANNOUNCES SERVICE AGREEMENT WITH ONCOTEST

Porto, Portugal – Phyzat announced today that it signed with Oncotest, a Charles River Company, a master service agreement to start in vivo tests of several of Phyzat’s proprietary siRNA compounds within Phyzat’s Primiphy project.

Patrício Soares-da-Silva, CSO at Phyzat, commented: “Oncotest has a unique patient derived xenografts collection and assay system that allows Phyzat to design tests in the Primiphy program and to strengthen our line of research. We look forward to this collaboration and expect to explore further Oncotest’s capacities in the continuation of the Primiphy project, while accelerating new projects.”

Aidan Synnott, Global Business Operations Lead at Charles River Laboratories, said: “Oncotest’s experimental systems are powerful tools to identify and characterize promising anti-cancer agents. We are happy to use these systems to test Phyzat’s RNA-based anti-cancer agents and thereby help Phyzat to reach their goals”

Phyzat is a biopharmaceutical company, incorporated in Porto to develop innovative RNA-based therapeutics with a discovery and clinical development program based on siRNA technologies. The Primiphy project is a discovery and pre-clinical development project of proprietary RNAi based therapeutic agents.

Oncotest is a pioneer in the field of patient-derived tumor xenografts (PDX) and provides tailored solutions for preclinical oncology research. In target validation, identification of the best drug candidates and the delivery of in-depth bioinformatics analyses Oncotest helps laying the groundwork for the successful planning of clinical trials. In November 2015 Oncotest became part of Charles River Laboratories International.

For inquiries contact:
paulo.osswald@phyzat.com
aidan.synnott@crl.com